Please assess the completion status of the following clinical trial:

Trial Title: Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Recurrent C. difficile infection (identified by positivity of C. difficile toxin in stools) with severe clinical picture (defined by the ESCMID Guidelines published in 2014 - Debast et al, Clin Microbiol Infect 2014)~* Possibility to undergo standard antimicrobial therapy for recurrent C. difficile infection Approval of informed consent~* Possibility to undergo protocol diagnostic and therapeutic procedures~* Stool negativity for parasites~* Stool negativity for Salmonella spp., Shigella spp., Yersinia enterocolitica, Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic Escherichia coli and other microorganisms except for C. difficile~* Blood negativity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level (VDRL).~Exclusion Criteria:~* Subjects \<18 years old~* Prior colectomy~* Negativity of C. difficile toxin in stools~* Mild clinical picture of C. difficile infection~* High risk of post-colonoscopy complications~* Other main gastrointestinal diseases (es. Crohn's disease or ulcerative colitis)~* Stool positivity for parasites~* Stool positivity for Salmonella spp., Shigella spp., Yersinia enterocolitica, Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic Escherichia coli and other microorganisms except for C. difficile~* Blood positivity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level (VDRL).~* Pregnancy or breastfeeding.~* Inability to follow protocol procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Multiple-infusion FMT (Type: EXPERIMENTAL): Repeated fecal infusions by colonoscopy. Before FMT, vancomycin is administered in all patients for 3 days
- Single-infusion FMT (Type: ACTIVE_COMPARATOR): Single fecal infusion by colonoscopy.Before FMT, vancomycin is administered in all patients for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).